GlassScriptPhysician profile
Komal R Patel
NPI 1154666238
$6,823.51
in general payments reported to CMS, 2019-2025
52 companies · $1,412 in 2025
The $1,412 reported for 2025 was more than what 86% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,122 · 2022: $1,387 · 2023: $1,300 · 2024: $1,603 · 2025: $1,412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,314.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $930.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $783.10 | 2021-2025 | Freestyle Libre 3, Proclaim, Ensite Precision |
| Lilly USA, LLC | $574.05 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $338.24 | 2021-2025 | Repatha, Tepezza, Prolia |
| Abbvie INC. | $304.79 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.96 | 2021-2025 | Jardiance, Synjardy |
| Radius Health, INC. | $262.58 | 2021-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $238.66 | 2021-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $214.49 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $210.97 | 2022-2025 | |
| Mannkind Corporation | $204.21 | 2021-2025 | Afrezza |
| Ascendis Pharma Endocrinology INC | $173.87 | 2023-2025 | Yorvipath |
| Zealand Pharma US, INC. | $150.56 | 2021-2022 | |
| Dexcom, INC. | $145.94 | 2021-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $124.51 | 2021-2024 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $120.99 | 2023-2024 | |
| Corcept Therapeutics | $117.36 | 2021-2025 | Korlym |
| Tandem Diabetes Care, INC. | $110.87 | 2021-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $109.68 | 2021-2024 | Tirosint, Licart, Tirosint |
| Antares Pharma, INC. | $97.11 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Kyowa Kirin, INC. | $96.24 | 2024-2025 | Crysvita |
| Currax Pharmaceuticals LLC | $95.83 | 2021-2023 | Contrave |
| Recordati_rare_diseases_inc. | $93.19 | 2023-2025 | Isturisa, Signifor Lar |
| Merck Sharp & Dohme LLC | $78.92 | 2021-2023 | Steglujan, Steglatro |
| Verity Pharmaceuticals INC. | $77.77 | 2024-2025 | Tlando |
| Tolmar Pharmaceuticals, INC. | $66.51 | 2022 | |
| Insulet Corporation | $66.23 | 2021-2023 | Omnipod |
| Acella Pharmaceuticals, LLC | $65.53 | 2022-2025 | NP Thyroid 60 |
| Alexion Pharmaceuticals, INC. | $60.74 | 2021-2025 | Strensiq |
| Amneal Pharmaceuticals LLC | $60.45 | 2021-2025 | Unithroid |
| Cequr Corporation | $56.90 | 2022-2025 | Cequr Simplicity |
| Amarin Pharma, INC. | $41.49 | 2021 | |
| Grt US Holding, INC. | $37.58 | 2022 | |
| Novartis Pharmaceuticals Corporation | $32.78 | 2024 | |
| Medtronic, INC. | $32.40 | 2022-2023 | Intellis Adaptivestim |
| Halozyme INC | $29.23 | 2023 | |
| Xeris Pharmaceuticals, INC. | $26.20 | 2025 | Gvoke Hypopen |
| Neurocrine Biosciences, INC. | $25.40 | 2025 | |
| Beta Bionics, INC. | $24.95 | 2024 | Ilet Bionic Pancreas |
| Soleno Therapeutics, INC. | $24.85 | 2025 | Vykat Xr |
| Nestle Healthcare Nutrition INC. | $23.71 | 2021 | |
| Amphastar Pharmaceuticals, INC. | $23.45 | 2024 | |
| Endo USA, INC. | $22.38 | 2024 | Aveed |
| Sequel Med Tech, LLC | $22.36 | 2025 | Twiist |
| Astellas Pharma US INC | $19.71 | 2024 | Veozah |
| Eisai INC. | $16.37 | 2021 | |
| Vivus LLC | $16.22 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $15.07 | 2023 | Evkeeza |
| Horizon Therapeutics Plc | $14.84 | 2023 | Tepezza |
| Azurity Pharmaceuticals, INC. | $14.65 | 2023 | Adthyza |
| Esperion Therapeutics, INC. | $14.43 | 2021 | |
| Roche Diabetes Care, INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Komal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.